expert perspectives: cdk 4/6 inhibitors for er breast cancer: current data and clinical use
Published 8 years ago • 4.8K plays • Length 17:54Download video MP4
Download video MP3
Similar videos
-
10:02
expert perspectives: cdk 4/6 inhibitors for er breast cancer: emerging data and future implications
-
13:05
expert perspectives: cdk 4/6 inhibitor therapy for er metastatic breast cancer
-
14:51
expert perspectives: targeting advanced er metastatic breast cancer with cdk 4/6 inhibitors
-
21:11
current clinical data for cdk 4/6 inhibitors in breast cancer
-
9:42
expert perspectives: rationale for cdk 4/6 inhibition in breast cancer
-
2:19
cdk 4/6 inhibitors for patients with recurrent er /her2- breast cancer: 2023 best of breast
-
7:59
what are cdk 4/6 inhibitors for breast cancer?
-
2:06
unmet needs and cdk4/6 inhibitors in hr /her2- early breast cancer
-
20:19
expert discussion on cdk 4/6 inhibition in breast cancer
-
29:09
interactive case: choosing and using cdk4/6 inhibitors in breast cancer - first-line therapy
-
7:40
cdk4/6 inhibitors in the first-line treatment setting
-
3:33
cdk 4/6 inhibitors in metastatic breast cancer
-
5:16
the clinical potential of cdk4/6 inhibitors
-
5:56
cdk 4/6 inhibitors for older women with hr-positive breast cancer
-
1:02:43
realizing the potential of cdk 4/6 inhibitor therapy in breast cancer: real-world data and evidence
-
4:50
expert report on tackling resistance to cdk4/6 inhibitors in er /her2-metastatic breast cancer
-
15:06
mechanistic activity and development history of cdk 4/6 inhibitors
-
9:02
cdk 4/6 inhibitors and identifying ild in patients
-
5:01
cdk4/6 inhibitors: sequencing endocrine therapy for metastatic breast cancer